Cancers (blood cancers)

MabThera SC (rituximab SC)

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

MabThera SC is a subcutaneous formulation of Ristova that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Ristova to be rapidly dispersed and absorbed over a greater area.

MabThera SC is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed/refractory follicular lymphoma, non-progressing (including stable disease) follicular lymphoma, and previously untreated diffuse large B-cell lymphoma.

In case of any adverse events or safety queries, please contact:

If you have a scientific query related to one of Roche's products, please contact:

M-PK-00001196

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsRoche careersPrivacy StatementLegal Statement